JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Guardant Health Inc

Slēgts

SektorsVeselības aprūpe

89.17 1.4

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

85.56

Max

90.78

Galvenie mērījumi

By Trading Economics

Ienākumi

-36M

-128M

Pārdošana

16M

281M

EPS

-0.5

Peļņas marža

-45.684

Darbinieki

2,490

EBITDA

-37M

-119M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+46.73% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 7. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-1.7B

12B

Iepriekšējā atvēršanas cena

87.77

Iepriekšējā slēgšanas cena

89.17

Ziņu noskaņojums

By Acuity

50%

50%

186 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Guardant Health Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 24. apr. 19:19 UTC

Iegādes, apvienošanās, pārņemšana

Intertek Group Rejects EQT's Revised Offer

2026. g. 24. apr. 23:37 UTC

Iegādes, apvienošanās, pārņemšana

Scoring the Cook Era -- Barrons.com

2026. g. 24. apr. 20:51 UTC

Iegādes, apvienošanās, pārņemšana

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026. g. 24. apr. 20:50 UTC

Tirgus saruna
Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 24. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 24. apr. 20:39 UTC

Iegādes, apvienošanās, pārņemšana

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026. g. 24. apr. 20:09 UTC

Peļņas

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

2026. g. 24. apr. 19:48 UTC

Tirgus saruna
Galvenie ziņu notikumi

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

2026. g. 24. apr. 19:25 UTC

Iegādes, apvienošanās, pārņemšana

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026. g. 24. apr. 19:25 UTC

Iegādes, apvienošanās, pārņemšana

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

2026. g. 24. apr. 19:22 UTC

Peļņas

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

2026. g. 24. apr. 19:06 UTC

Peļņas

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

2026. g. 24. apr. 19:05 UTC

Tirgus saruna

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

2026. g. 24. apr. 18:30 UTC

Iegādes, apvienošanās, pārņemšana

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

2026. g. 24. apr. 18:28 UTC

Iegādes, apvienošanās, pārņemšana

Intertek Rejects Revised EQT Offer

2026. g. 24. apr. 18:12 UTC

Tirgus saruna

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

2026. g. 24. apr. 18:06 UTC

Tirgus saruna

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

2026. g. 24. apr. 17:42 UTC

Peļņas

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

2026. g. 24. apr. 17:28 UTC

Peļņas

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

2026. g. 24. apr. 17:28 UTC

Tirgus saruna

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

2026. g. 24. apr. 17:12 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 24. apr. 17:11 UTC

Tirgus saruna

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

2026. g. 24. apr. 17:09 UTC

Tirgus saruna
Peļņas

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

2026. g. 24. apr. 17:09 UTC

Iegādes, apvienošanās, pārņemšana

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026. g. 24. apr. 17:06 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

2026. g. 24. apr. 16:51 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

2026. g. 24. apr. 16:20 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2026. g. 24. apr. 16:20 UTC

Tirgus saruna
Galvenie ziņu notikumi

Financial Services Roundup: Market Talk

2026. g. 24. apr. 16:20 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 24. apr. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Guardant Health Inc Prognoze

Cenas mērķis

By TipRanks

46.73% augšup

Prognoze 12 mēnešiem

Vidējais 128.93 USD  46.73%

Augstākais 175 USD

Zemākais 86.72 USD

Pamatojoties uz 18 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Guardant Health Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

18 ratings

17

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

38.86 / 47.41Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

186 / 348 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat